SKI Market

A+| A| A-| Skip to Main Content

Indian Indices

Sensex

76,765.92 -69.86
( -0.09%)

Global Indices

Nasdaq

52,223.83 255.58
(0.49%)

Dow Jones

7,434.43 1.45
(0.02%)

Hang Seng

62,158.55 -2,772.64
(-4.27%)

Nikkei 225

10,879.18 97.43
(0.90%)

Forex

USD-INR

96.67 0.19
(0.20%)

EUR-INR

110.18 0.12
(0.10%)

GBP-INR

129.04 -0.01
(0.00%)

JPY-INR

0.59 0.00
(-0.04%)

YOU ARE HERE :
HOME
Markets
Equity
Company News Details

EQUITY - MARKET SCREENER

Industry :

BSE Code

ISIN Demat

Book Value()

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

EPS(TTM)

Face Value()

Div & Yield %

Back

modern engineering & projects limited

Glenmark receives USFDA approval for expanded use of RYALTRIS® for pediatric patients

Jul 21,2026

Glenmark Specialty S.A. (Glenmark) today announced that U.S. FDA has approved the expanded use of RYALTRIS® (olopatadine hydrochloride and mometasone furoate) Nasal Spray, 665 mcg/25 mcg per spray, for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years.

With this approval, RYALTRIS® is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population.

76,765.92 -69.86 ( -0.09%)

52,223.83 255.58 (0.49%)

7,434.43 1.45 (0.02%)

62,158.55 -2,772.64 (-4.27%)

10,879.18 97.43 (0.90%)

96.67 0.19 (0.20%)

110.18 0.12 (0.10%)

129.04 -0.01 (0.00%)

0.59 0.00 (-0.04%)